Effects of an 8-month exercise intervention on physical capacity, NT-proBNP, physical activity levels and quality of life data in patients with pulmonary arterial hypertension by NYHA class.

This article provides descriptive detailed (pre and post) values of physical capacity variables, NT-proBNP, physical activity levels and quality of life in patients with pulmonary arterial hypertension (PH) (both, intervention and control group) by New York Heart Association (NYHA) class before and after an 8-month exercise intervention. The data are supplemental to our original Randomized Controlled Trial (RCT) entitled "Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial" (L. González-Saiz, C. Fiuza-Luces, F. Sanchis-Gomar, A. Santos-Lozano, C.A. Quezada-Loaiza, A. Flox-Camacho, D. Munguía-Izquierdo, I. Ara, A. Santalla, M. Morán, P. Sanz-Ayan, P. Escribano-Subías, A. Lucia A, 2017) [1].

RCT Entities:   Population Interventions Outcomes

Specifications Table

Value of the data

Data presented here provide the descriptive overview of the PH patients by NYHA class involved in an exercise RCT.

We describe the changes in physical capacity-related primary outcomes (peak watts in leg and bench press) and the changes in physical capacity-related secondary outcomes [maximal inspiratory pressure (PImax), 6-minute walking distance (6MWD), and performance time in the 5-repetition sit-to-stand (5-STS) test] of the PAH patients by NYHA class involved in the RCT (control vs. intervention).

We describe values of physical activity (PA) levels (min/day in inactivity and moderate-vigorous PA) of PH patients by NYHA class involved in the RCT (control vs. intervention).

We show the values of health related quality of life [HRQoL, (mental and physical components of SF-36 questionnaire)] of PH patients by NYHA class involved in the RCT (control vs. intervention).

This data could be useful to physicians to make comparisons with other cohort datasets and so to contribute to the knowledge of the PA effect in PH patients by NYHA class.

Data

Descriptive values of physical capacity-related variables, NT-ProBNP, cardiopulmonary exercise capacity, PA levels and HRQoL of PAH patients involved in the RCT [2] (ClinicalTrials.gov ID: NCT02288442) conducted from January 2015 to June 2016 at the Hospital 12 de Octubre (Madrid, Spain) following the Consolidated Standards of Reporting Trials (CONSORT) guidelines [3] are shown in Table 1.

Table 1

Results of the primary and secondary end points by group and NYHA class.

NYHA Class I

NYHA Class I-II

NYHA Class II

NYHA Class II-III

NYHA Class III

End points

Group

N with initial data

Baseline

Post

N with initial data

Baseline

Post

N with initial data

Baseline

Post-

N with initial data

Baseline

Post

N with initial data

Baseline

Post

Primary

Leg press

Control

6

551±285

583±200

2

413±178

347

9

308±138

323±130

–

–

–

2

206±136

138

(peak watts)

Exercise

3

372±96

471±130

2

451±437

666±584

11

307±234

507±297

4

310±221

470±241

–

–

–

Bench press

Control

5

297±130

325±135

2

101±28

93

10

119±79

121±59

–

–

–

2

74±34

65

(peak watts)

Exercise

3

151±113

187±99

2

175±174

230±212

11

113±76

173±118

4

109±83

162±72

–

–

–

Secondary

Blood variables

NT-proBNP

Control

4

63±39

35±112

2

141±55

112

8

270±277

427±560

–

–

–

2

344±337

598

(pg/mL)

Exercise

3

560±327

710±558

2

256±193

193±117

11

235±210

210±177

4

264 ±205

263±165

–

–

–

CET

VO2peak

Control

6

27.3±5.4

27.9±5.9

2

18.2±0.3

19

9

16.5±2.8

15.5±3.12

–

–

–

2

13±1.4

14

(mL/kg/min)

Exercise

3

16.7±0.56

19±1

2

17.3±3.7

21.3±1.7

11

15.2±3.4

17.3±2.9

4

15.2±4.6

17.4±4.2

–

–

–

PETCO2@AT (mmHg)

Control

6

28±3

30±2

2

26±1

27

8

32±6

30±7

–

–

–

2

21±5

22

Exercise

3

24±6

24±6

2

25±2

23±3

11

28±7

27±7

4

27±4

26±7

–

–

–

PETO2@AT

Control

6

113±4

111±2

2

115±2

113

8

110±5

111±5

–

–

–

2

119±4

118

(mmHg)

Exercise

3

116±6

116±3

2

115±5

118±3

11

113±6

115±6

4

114±6

113±8

–

–

–

VE/VCO2@AT

Control

6

42±7

39±4

2

42±5

37±4

8

38±7

39±9

–

–

–

2

52±16

52

Exercise

3

45±11

45±12

2

43±2

47±5

11

41±11

44±13

4

43±7

43±10

–

–

VE/VO2@AT

Control

6

45±9

43±4

2

45±2

43

8

40±6

43±10

–

–

–

2

58±19

62

Exercise

3

52±16

54±16

2

46±5

53±7

11

46±12

49±13

4

48±11

48±17

–

Other physical capacity variables

PImax

Control

6

97±32

100±34

2

66±10

60

9

68±24

69±26

–

–

–

2

38±27

83

(cmH2O)

Exercise

3

62±33

102±41

2

74±66

105±90

11

81±39

110±25

4

70±26

117±16

–

–

–

6MWD

Control

6

639±97

620±154

2

579±43

549

10

497±75

491±45

–

–

–

2

480±17

492

(meters)

Exercise

3

549±36

572±15

2

504±77

549±43

11

495±76

512±74

4

475±73

517±90

–

–

–

5-STS (performance time, seconds**)

Control

6

6.2±1.2

5.9±1

2

5.1±1

5.2±1

10

7.8±1.5

7.6±1.2

–

–

–

2

6.8

8.1

Exercise

3

6.5±2

5.8±2

2

6.5±2

5.5±1

11

8±1.5

6.1±1.3

3

7.3±1

6.1±1

–

–

–

PA levels

Inactivity time (min/day)

Control

3

531±154

573±100

1

605

674

7

549±109

581±76

–

–

–

2

604±26

668±61

Exercise

3

562±40

583±53

2

621±136

409±12

6

554±93

536±85

4

573±148

630±101

–

–

–

MVPA

Control

3

42±29

26±20

1

42

49

6

45±26

32±21

–

–

–

2

20±22

16±10

(min/day)

Exercise

3

58±12

13±11

2

42±22

49±5

6

28±19

42±18

4

44±28

34±7

–

–

–

HRQoL (SF-36)

Mental

Control

3

56±6

53±7

1

58

62

7

47±12

53±7

–

–

–

2

49±12

38

component

Exercise

3

49±12

38

2

54±4

59±5

10

45±10

53±10

4

56±6

52±9

–

–

–

Physical component

Control

3

44±4

49±6

1

50

46

8

39±7

43±7

–

–

–

2

35±1

41

Exercise

3

39±9

42±8

2

45±0.2

50±1

10

37±7

42±6

4

30±6

33±9

–

–

–

Data are mean±SD. Abbreviations: 6MWD, 6-minute walking distance; 5-STS, 5-repetition sit-to-stand; CET, cardiopulmonary exercise testing: HRQoL, health-related quality of life; MVPA, moderate-vigorous physical activity; NT-proBNP (pg/mL), N-terminal pro-B-type-natriuretic peptide; PETCO2@AT, end-tidal pressure of carbon dioxide at the anaerobic threshold; PETO2@AT, end-tidal pressure of oxygen at the anaerobic threshold; PImax, maximal inspiratory pressure; SF-36, Short Form-36 Item Health Survey; VE/VCO2@AT, ventilatory equivalent for carbon dioxide at the anaerobic threshold; VE/VO2@AT, ventilatory equivalent for oxygen at the anaerobic threshold; VO2peak, peak oxygen uptake.

Experimental design, materials and methods

20 PH patients were involved in the intervention group of the RCT and 20 PH patients in the control group. The RCT intervention lasted 8 weeks and included 3 main components: aerobic and muscle resistance, and specific inspiratory muscle training. All sessions were supervised by experienced fitness instructors. Data outcome (by order of aquisition) were: i) blood sampling for NT-proBNP determination, PImax, 6MWD, muscle power, 5-STS, and distribution of HRQoL questionnaire (1st day); ii) cardiopulmonary exercise testing (after 2–3 days to allow recovery from power testing); and iii) seven days of accelerometry recording for objective PA determination. Please see Gonzalez-Saiz et al. (2017) [1] for detailed information.

Subject area	Medicine
More specific subject area	Cardiology
Type of data	Table
How data was acquired	Functional clinical assessment of the patients and sample blood analysis
Data format	Descriptive data: mean±SD
Experimental factors	Data of the patients with pulmonary arterial hypertension by New York Heart Association class
Experimental features	Randomized Controlled Trial
Data source location	Madrid, Spain
Data accessibility	The data are accessible within the article